10-K: Xenon Pharmaceuticals Reports Full Year 2024 Results, Highlights Azetukalner Progress

Sentiment:

Annual Results 27 February 2025 4:39 PM

📋All filings for Xenon Pharmaceuticals INC

Xenon Pharmaceuticals' 10-K filing details the company's financial results for 2024 and provides updates on its pipeline, particularly the progress of azetukalner in epilepsy and neuropsychiatric disorders.

Capital raiseThe company may seek additional capital due to favorable market conditions or strategic considerations, even if it believes that it has sufficient funds for its current or future operating plans.The terms of any financing arrangements the company enters into may adversely affect the holdings or the rights of its shareholders and the issuance of additional securities, whether equity or debt, by the company, or the possibility of such issuance, may cause the market price of its common shares to decline.The company could also be required to seek funds through collaborations or marketing, distribution or licensing arrangements, or royalty-based financings with third parties, and it may have to relinquish valuable rights to its technologies, future revenue streams or product candidates, or grant licenses on terms that may not be favorable to it.

Summary

Xenon Pharmaceuticals, a neuroscience-focused biopharmaceutical company, filed its 10-K report for the fiscal year ended December 31, 2024.
The company is advancing a novel product pipeline to address neurological and psychiatric disorders, including epilepsy and depression.
Azetukalner, a Kv7 potassium channel opener, is the company's most advanced product candidate, in Phase 3 clinical development for focal onset seizures (FOS) and primary generalized tonic-clonic seizures (PGTCS), as well as major depressive disorder (MDD) and bipolar depression (BPD).
Phase 3 clinical studies in FOS (X-TOLE2 and X-TOLE3) are ongoing, with topline data expected in the second half of 2025.
The Phase 3 X-ACKT clinical study for PGTCS continues to enroll patients.
A Phase 3 program evaluating azetukalner in MDD is underway, and plans for a Phase 3 program in BPD are in place, with the first clinical studies expected by mid-year.
The company is also expanding its portfolio of ion channel modulators, with IND-enabling work underway for Kv7, Nav1.7, and Nav1.1 development candidates, with the goal of filing multiple INDs in 2025.
Neurocrine Biosciences' NBI-921355, a Nav1.2/1.6 sodium channel inhibitor being developed for epilepsy under a collaboration agreement with Xenon, has progressed into a Phase 1 clinical study, triggering an anticipated $7.5 million milestone payment to Xenon.
The company had net losses of $234.3 million in 2024, $182.4 million in 2023 and $125.4 million in 2022, and an accumulated deficit of $899.5 million as of December 31, 2024.
As of December 31, 2024, Xenon had cash, cash equivalents, and marketable securities totaling $754.4 million, which are expected to fund operations for at least the next 12 months.
The company relies on third-party contract manufacturers (CMOs) for the production of its product candidates.
As of December 31, 2024, Xenon had 327 employees, including 316 full-time and part-time permanent employees.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While there is progress in the pipeline and a strong cash position, the company is still operating at a loss and faces significant risks and uncertainties.

Positives

Azetukalner is in Phase 3 clinical development for multiple indications.
The company is expanding its pipeline with new ion channel modulators.
The collaboration with Neurocrine Biosciences is progressing, with NBI-921355 entering Phase 1 clinical study.
Xenon has a strong cash position of $754.4 million, expected to fund operations for at least the next 12 months.

Negatives

Xenon has incurred significant net losses in recent years and has an accumulated deficit of $899.5 million as of December 31, 2024.
The company has no products approved for commercial sale and has not generated any revenue from product sales to date.
The company relies on third-party contract manufacturers (CMOs) for the production of its product candidates, which introduces risks related to supply and quality control.

Risks

Clinical trials may fail to demonstrate the safety and efficacy of product candidates.
The regulatory approval processes are lengthy, time-consuming, and inherently unpredictable.
The company may face substantial competition in the markets for its product candidates.
The company may need to raise additional funding, which may not be available on acceptable terms, if at all.
The company is subject to evolving global laws and regulations relating to privacy, data protection and information security, which may require the company to incur substantial compliance costs.
The company's business and operations could suffer in the event of an actual or perceived information security incident such as a cybersecurity breach, system failure, or other compromise of the company's systems and/or information, including information held by a third-party contractor or vendor.

Future Outlook

The company expects to continue to incur significant losses for the foreseeable future as it continues its research and development of, and seeks regulatory approvals for its product candidates.

Industry Context

The biotechnology and pharmaceutical industries are highly competitive and are characterized by rapidly advancing technologies and a strong emphasis on proprietary products.

Comparison to Industry Standards

The document mentions several companies developing product candidates for the treatment of epilepsy, MDD, and bipolar depression, including AbbVie Inc., Biohaven Ltd., Neurona Therapeutics Inc., NeuShen Therapeutics, Inc., Praxis Precision Medicines, Inc., QurAlis Corporation, Rapport Therapeutics, Inc., SK Life Science Inc., Supernus Pharmaceuticals, Inc. and Zhimeng Biopharma, Inc., Alto Neuroscience, Inc., Axsome Therapeutics, Inc., Intra-Cellular Therapies, Inc., Johnson & Johnson Innovative Medicine, Neumora Therapeutics, Inc., and Neurocrine Biosciences, Inc., and NRx Pharmaceuticals, Inc.
These companies represent the competitive landscape in which Xenon operates, and their progress and success could impact Xenon's market opportunities.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
Chief Financial Officer	Sherry Aulin	TBD	June 30, 2025	Sherry Aulin is resigning from her position as Chief Financial Officer, effective June 30, 2025.

Stakeholder Impact

Shareholders may experience dilution from future equity offerings.
Employees may be affected by changes in compensation and benefits programs.
Patients may benefit from the development of new treatments for neurological and psychiatric disorders.
Collaborators and suppliers may be impacted by changes in the company's business strategy.

Next Steps

Continue Phase 3 clinical studies in FOS (X-TOLE2 and X-TOLE3), with topline data expected in the second half of 2025.
Continue Phase 3 X-ACKT clinical study for PGTCS.
Initiate Phase 3 clinical studies in BPD by mid-year.
Advance Kv7, Nav1.7, and Nav1.1 development candidates into IND-enabling studies, with the goal of filing multiple INDs in 2025.
Support Neurocrine Biosciences in the Phase 1 clinical study of NBI-921355.

Key Dates

Date	Description
November 5, 1996	Xenon Bioresearch Inc. was incorporated in the Province of British Columbia.
May 17, 2000	Xenon Bioresearch Inc. continued from British Columbia to the federal jurisdiction pursuant to Section 187 of the Canada Business Corporations Act, or the CBCA, on May 17, 2000 and concurrently changed its name to Xenon Genetics Inc.
July 10, 2000	Xenon Genetics Inc. registered as an extra-provincial company in British Columbia.
August 24, 2004	Xenon Genetics Inc. changed its name to Xenon Pharmaceuticals Inc.
April 2017	Xenon entered into an asset purchase agreement with 1st Order Pharmaceuticals, Inc. to acquire all rights with respect to azetukalner.
December 2019	Xenon entered into a license and collaboration agreement with Neurocrine Biosciences to develop treatments for epilepsy.
January 2021	Amendment No. 1 to the License and Collaboration Agreement, dated December 2, 2019, by and between Xenon Pharmaceuticals Inc. and Neurocrine Biosciences, Inc.
January 2022	Xenon received an aggregate milestone payment of $15.0 million in the form of a $6.75 million payment in cash and a $8.25 million equity investment, based on the U.S. Food and Drug Administration's, or FDAs, acceptance of a protocol amendment to expand the study population of a clinical trial in pediatric patients with SCN8A-DEE.
February 2022	Amendment #2, dated February 25, 2022, to the License and Collaboration Agreement, dated December 2, 2019, by and between Xenon Pharmaceuticals Inc. and Neurocrine Biosciences, Inc.
June 2022	The agreement also included a multi-year research collaboration to discover, identify and develop additional novel Nav1.6 and Nav1.2/1.6 inhibitors, which was completed in June 2022.
January 31, 2022	The Clinical Trials Regulation EU No 536/2014, or the CTR, which replaced the Clinical Trials Directive, entered into application on January 31, 2022, harmonizes the procedures for the submission, assessment and monitoring of clinical drug trials in the EU, thus simplifying the current rules for clinical trial authorization and standards of performance.
January 31, 2023	As of January 31, 2023, all new CTA applications had to be submitted via CTIS and be made pursuant to the CTR.
January 31, 2025	From and after January 31, 2025, all clinical trials (including those approved under the Clinical Trial Directive (now replaced by the CTR)) need to comply with the CTR and be recorded in CTIS.
February 2025	NBI-921355, a Nav1.2 and Nav1.6 sodium channel inhibitor in development for the potential treatment for certain types of epilepsy, has progressed into a Phase 1 clinical study in healthy adult participants, triggering an anticipated $7.5 million milestone payment to us.
February 24, 2025	The number of common shares of the Registrant outstanding as of February 24, 2025 was 76,542,811.
February 27, 2025	On February 27, 2025, the Board of Directors of the Company approved the 2025 Inducement Equity Incentive Plan (the '2025 Inducement Plan').
June 2032	The term of the lease for the headquarters in Burnaby, British Columbia expires in June 2032.
November 2027	The term of the lease for the office space in Needham, Massachusetts expires in November 2027.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.